Human medicines European public assessment report (EPAR): Aqumeldi, enalapril maleate, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Omjjara, momelotinib, Date of authorisation: 25/01/2024, Revision: 1, Status: Authorised

Medicine shortage communication (MSC): Fiasp PumpCart and NovoRapid PumpCart

NovoRapid PumpCart (insulin aspart)

Fiasp PumpCart (insulin aspart)

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0079/2024

EMEA-003130-PIP02-23

Agenda - EMA’s 30th anniversary scientific conference

Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised

Careers